Lyumjev™ (insulin lispro – aabc) injection

100 units/mL, 200 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

LYUMJEV™ (insulin lispro-aabc): Marketing Approval

The approval of Lyumjev by the US FDA was communicated on June 15, 2020. Lyumjev is approved for the treatment of adults with diabetes.

Lyumjev - Marketing Approval

The approval of Lyumjev for the treatment of adults with T1DM or T2DM was communicated by FDA on June 15, 2020. Lyumjev is marketed under the brand name Lyumjev™ (insulin lispro-aabc) injection.1

Enclosed Prescribing Information

LYUMJEV™ (insulin lispro-aabc) injection, for subcutaneous or intravenous use, Lilly

Reference

1. FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin. Press release. Eli Lilly and Company; June 15, 2020. Accessed July 3, 2020. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lyumjevtm-insulin-lispro-aabc-injection-lillys-new

Glossary

Lilly = Eli Lilly and Company

Lyumjev = Lyumjev™ (insulin lispro-aabc)

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Date of Last Review: July 03, 2020


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Chat with us

Submit a Request

Visit Us @LillyMedical